Drug Trial Radar · NCT06503679
A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Jan 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
49
Actual
Start
Jul 16, 2024
Primary completion
Dec 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyIndustry
- Sponsor type
- Industry
- First posted
- Jul 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study is to assess the safety and tolerability and pharmacokinetics of LY4100511 (DC-853) when administered alone or in the presence of cytochrome P450 substrates in healthy participants.
Conditions
- Healthy
Interventions
LY4100511 (DC-853) Dose 1Drug
Administered orally
LY4100511 (DC-853) Dose 2Drug
Administered orally
LY4100511 (DC-853) Dose 3Drug
Administered orally
MidazolamDrug
Administered orally
RepaglinideDrug
Administered orally
DigoxinDrug
Administered orally
RosuvastatinDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK): Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC [0-∞]) of Midazolam, in the absence or presence of steady-state LY4100511Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose
- Pharmacokinetics (PK): Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC [0-∞]) of 1-Hydroxymidazolam, in the absence or presence of steady-state LY4100511Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose
- Pharmacokinetics (PK): Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC [0-∞]) of Repaglinide, in the absence or presence of steady-state LY4100511Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose
- Pharmacokinetics (PK): Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC [0-∞]) of Digoxin, in the absence or presence of steady-state LY4100511Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose
- PK: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration (AUC[0-tlast]) of Midazolam, in the absence or presence of steady-state LY4100511Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose
- PK: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration (AUC[0-tlast]) of 1-Hydroxymidazolam, in the absence or presence of steady-state LY4100511Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose
- PK: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration (AUC[0-tlast]) of Repaglinide,in the absence or presence of steady-state LY4100511Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose
- PK: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration (AUC[0-tlast]) of Digoxin, in the absence or presence of steady-state LY4100511Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose
- PK: Maximum Observed Concentration (Cmax) of Midazolam, in the absence or presence of steady-state LY4100511Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose
- PK: Maximum Observed Concentration (Cmax) of 1-Hydroxymidazolam, in the absence or presence of steady-state LY4100511Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose
- PK: Maximum Observed Concentration (Cmax) of Repaglinide, in the absence or presence of steady-state LY4100511Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose
- PK: Maximum Observed Concentration (Cmax) of Digoxin, in the absence or presence of steady-state LY4100511Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fortrea Clinical Research Unit
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.